Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Keyword(s):
Key Points Enasidenib inhibits mIDH2, leading to leukemic cell differentiation with emergence of functional mIDH2 neutrophils in rrAML patients. RAS pathway mutations and increased mutational burden overall are associated with a decreased response rate to mIDH2 inhibition.
2003 ◽
Vol 105
(2)
◽
pp. 232-240
◽
2017 ◽
Vol 14
(2)
◽
pp. 1081-1085
◽
2014 ◽
Vol 20
(2)
◽
pp. S158
2017 ◽
Vol 49
(7)
◽
pp. 1578-1582
◽
Keyword(s):